Orphazyme’s arimoclomol receives US fast track designation in amyotrophic lateral sclerosis


22 May 2020 - Orphazyme announces that the Company has received fast track designation from the US FDA for the development of arimoclomol for the treatment of amyotrophic lateral sclerosis.

Arimoclomol has also received fast track status from the FDA for the treatment of Niemann-Pick disease type C and sporadic inclusion body myositis.

Read Orphazyme press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track